Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
20.34
-0.23 (-1.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
7 Undervalued Biotech Stocks to Buy Before They Boom
July 25, 2022
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.
Via
InvestorPlace
7 Best Biotech Stocks to Buy in July 2022
July 08, 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.
Via
InvestorPlace
The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
July 07, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022
June 24, 2022
Upgrades
Via
Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
June 21, 2022
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...
Via
Benzinga
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
June 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Exelixis-BioInvent Establish Immuno-Oncology Pact
June 16, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on
May 24, 2022
Good morning, trader! We're jumping into trading on Tuesday with an overview of the biggest pre-market stock movers this morning!
Via
InvestorPlace
Earnings Scheduled For February 17, 2022
February 17, 2022
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.
Via
Benzinga
This Biotech Looks Good With Increased M&A activity
May 20, 2022
Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for...
Via
Talk Markets
12 Health Care Stocks Moving In Thursday's Intraday Session
May 19, 2022
Via
Benzinga
Exelixis: Q1 Earnings Insights
May 10, 2022
Exelixis (NASDAQ:EXEL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings by...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
May 03, 2022
Via
Benzinga
7 Top-Rated Biotech Stocks to Buy for Q2
April 21, 2022
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.
Via
InvestorPlace
Friday Markets News
March 25, 2022
Methane leaks in the Permian Basin are 6 times higher than estimates.
Via
Talk Markets
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
March 25, 2022
Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have
Via
Benzinga
Flood Helping Ukraine
March 24, 2022
Emerging markets are gaining as mature markets look risky.
Via
Talk Markets
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
March 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
March 15, 2022
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...
Via
Benzinga
Futures Flat As Traders Brace For Op-Ex Volatility, More Ukraine Headlines
February 18, 2022
In the latest geopolitical developments Russian Foreign Minister Sergei Lavrov agreed to meet US Secretary of State Antony Blinken for talks in Europe next week; German Chancellor Olaf Scholz will host...
Via
Talk Markets
Exelixis: Q4 Earnings Insights
February 17, 2022
Exelixis (NASDAQ:EXEL) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings...
Via
Benzinga
Earnings Preview For Exelixis
February 16, 2022
Exelixis (NASDAQ:EXEL) is set to give its latest quarterly earnings report on Thursday, 2022-02-17. Here's what investors need to know before the announcement. Analysts estimate that Exelixis will...
Via
Benzinga
Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial
February 15, 2022
Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (...
Via
Benzinga
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
January 10, 2022
Pfizer and Bayer inked deals with several companies in gene-editing.
Via
Investor's Business Daily
A Peek Into The Markets: US Stock Futures Edge Higher; Crude Oil Up 0.5%
January 10, 2022
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the three major averages recorded losses last week. Investors are awaiting earnings...
Via
Benzinga
Early Monday Report - More Moves Out Of China
January 09, 2022
Before it even turned Monday in the West, China insurers are feeling the heat.
Via
Talk Markets
Post-Fed Thursday
January 06, 2022
Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today.
Via
Talk Markets
7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now
January 03, 2022
These cheap stocks are trading at highly attractive prices and have the potential to break through this year.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.